Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAK423A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| QAK423A Arm A | EXPERIMENTAL | - |
| QAK423A Arm B | EXPERIMENTAL | - |
| QAK423A Arm C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| QAK423A | DRUG | - |
Inclusion Criteria: Part A: * Healthy, male subjects aged 18-55 years of age able to provide written informed consent prior to study participation and determined as in good health by past medical history, physical examination, ECG, laboratory tests and urinalysis. Parts B and C: * Male or female...
QAK423A is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
QAK423A is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS.
QAK423A is in Phase 1 clinical development. It is an investigational drug and has not yet been approved for any use. The Phase 1 trial has been completed.
QAK423A has one completed Phase 1 clinical trial, identified as NCT01197287. This trial evaluated the safety, tolerability, and pharmacokinetics of QAK423A in healthy volunteers and patients with Chronic Obstructive Pulmonary Disease (COPD).
QAK423A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, and its safety and efficacy have not been established for any indication.